4.4 Review

Artificial intelligence in breast imaging

Journal

CLINICAL RADIOLOGY
Volume 74, Issue 5, Pages 357-366

Publisher

W B SAUNDERS CO LTD
DOI: 10.1016/j.crad.2019.02.006

Keywords

-

Funding

  1. National Institute for Health Research
  2. Cambridge School of Clinical Medicine, Frank Edward Elmore Fund
  3. Medical Research Council's Doctoral Training Partnership [1966157]
  4. EPSRC Centre for Mathematical and Statistical Analysis of Multimodal Clinical Imaging [EP/N014588/1]
  5. EPSRC [EP/N014588/1] Funding Source: UKRI
  6. MRC [1966157] Funding Source: UKRI

Ask authors/readers for more resources

This article reviews current limitations and future opportunities for the application of computer-aided detection (CAD) systems and artificial intelligence in breast imaging. Traditional CAD systems in mammography screening have followed a rules-based approach, incorporating domain knowledge into hand-crafted features before using classical machine learning techniques as a classifier. The first commercial CAD system, ImageChecker M1000, relies on computer vision techniques for pattern recognition. Unfortunately, CAD systems have been shown to adversely affect some radiologists' performance and increase recall rates. The Digital Mammography DREAM Challenge was a multidisciplinary collaboration that provided 640,000 mammography images for teams to help decrease false-positive rates in breast cancer screening. Winning solutions leveraged deep learning's (DL) automatic hierarchical feature learning capabilities and used convolutional neural networks. Start-ups Therapixel and Kheiron Medical Technologies are using DL for breast cancer screening. With increasing use of digital breast tomosynthesis, specific artificial intelligence (AI)-CAD systems are emerging to include iCAD's PowerLook Tomo Detection and ScreenPoint Medical's Transpara. Other Al-CAD systems are focusing on breast diagnostic techniques such as ultrasound and magnetic resonance imaging (MRI). There is a gap in the market for contrast-enhanced spectral mammography Al-CAD tools. Clinical implementation of Al-CAD tools requires testing in scenarios mimicking real life to prove its usefulness in the clinical environment. This requires a large and representative dataset for testing and assessment of the reader's interaction with the tools. A cost-effectiveness assessment should be undertaken, with a large feasibility study carried out to ensure there are no unintended consequences. Al-CAD systems should incorporate explainable Al in accordance with the European Union General Data Protection Regulation (GDPR). (C) 2019 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available